Study on the Effectiveness and Safety of Temporal Interference Stimulation in Treating Patients with Severe Consciousness Disorders

Launched by HUASHAN HOSPITAL · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called temporal interference stimulation for patients with severe consciousness disorders, such as being in a minimally conscious state or vegetative state for at least 28 days. The goal is to see if this treatment is both effective and safe for individuals aged 18 to 65 who meet specific health criteria. Participants will need to have stable vital signs and be eligible for MRI scans, and their family members will need to give written consent for them to join the study.

If you or someone you know is considering participating, it’s important to note that certain conditions might prevent eligibility. For instance, individuals with significant heart, lung, or kidney issues, recent serious infections, or those with implanted devices like pacemakers cannot take part. The study is not yet recruiting, but once it begins, participants can expect to undergo this new treatment and be monitored for any effects on their condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Severe consciousness disorder patients aged 18 to 65 years old, regardless of gender;
• • Patients with severe consciousness disorders, namely a minimally conscious state or vegetative state that lasts for 28 days or more;
• • Patients with normal body temperature, stable vital signs, spontaneous breathing, tracheotomy without the use of a metal cannula and with a small amount of sputum, and who are eligible for magnetic resonance imaging (MRI) examination;
• • Written informed consent obtained from the patient's family members in advance.
• Exclusion Criteria:
• • Individuals with a previous history of significant neuropsychiatric and other major disorders such as those involving the heart, lung, liver, and kidney;
• • Those who have undergone V-P shunt or Ommaya reservoir implantation and other procedures that may influence the analysis of magnetic resonance scanning signals;
• • Patients who are scheduled for V-P shunt or Ommaya reservoir implantation in the near future;
• • Pregnant women;
• • Those who have participated in other drug or device clinical trials;
• • Patients with poorly controlled epilepsy in the recent period;
• • Those with infections at the TI stimulation site or compromised skin integrity at the electrode placement site;
• • Those currently taking medications prone to inducing epilepsy, such as quinolone drugs;
• • Those with intracranial infections, intracranial tumors, or metallic objects within the cranium;
• • Those allergic to electrode gel or adhesives;
• • Those with implanted electronic devices within the body;
• • Those with severe cardiac disorders and those equipped with cardiac pacemakers.